Deep Brain Stimulation of the Bilateral Habenula for Treatment-Refractory Obsessive-Compulsive Disorder

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

6 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-03-01

Study Completion Date

2020-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Deep brain stimulation (DBS) offers an effective and safe treatment for patients with debilitating, otherwise treatment-refractory obsessive-compulsive disorder(OCD). Although several target areas for DBS have been used for OCD, such as the ventral capsule/ventral striatum and the subthalamic nucleus, not all patients show a clinical response, varying from 10% to 61.5%. Exploring new DBS targets may be a key approach to improve this situation. The habenula is an evolutionarily conserved structure playing an important role in depression, punishment avoiding, reward, addiction, pain and circadian rhythms. The habenula can be considered a promising target for OCD treatment based on the following hypotheses and clinical observations.

1. The lateral habenula DBS has significant clinical antidepressant effects.
2. The habenula plays an important role in the regulation of dopamine and serotonin systems.
3. Selective serotonin reuptake inhibitors, the first line treatment for OCD, are commonly used to treat clinical depression.
4. The habenula serves as a 'negative reward center' that mediates or moderates stress, negative emotions and thoughts, aversive learning, and goal-directed behavior, which are core clinical symptoms and signs of OCD.
5. In our hospital, DBS of the habenula produced a significant improvement in OCD symptoms in one patient who failed to respond to other treatments, including capsulotomy either alone or in combination combined with cingulumotomy.

These theoretical and clinical considerations indicate that the habenula can be seen as a promising DBS target for OCD treatment. This study is focused on the effectiveness of bilateral DBS of the habenula for patients with treatment-refractory OCD. Furthermore, the study is aimed at exploring the influence of DBS of the habenula on brain activity and cognition.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

China Refractory Obsessive-Compulsive Disorder Deep Brain Stimulation Study

NCT02398318

Obsessive Compulsive Disorder

WITHDRAWN PHASE2/PHASE3

DBS for Treatment-resistant Obsessive-compulsive Disorder

NCT06360991

Obsessive-Compulsive Disorder (OCD)

NOT_YET_RECRUITING NA

Novel Deep Brain Stimulation in Ventral Capsule and Stratum for Refractory Obsessive-Compulsive Disorder

NCT02590445

Obsessive-Compulsive Disorder

UNKNOWN PHASE2/PHASE3

The Efficacy and Mechanism of DBS in VIC and NAcc for Refractory OCD

NCT04228744

Obsessive-Compulsive Disorder Deep Brain Stimulation

UNKNOWN NA

The Efficacy and Safety of ALIC/NAcc-DBS for Treatment-refractory OCD

NCT04967560

Obsessive-Compulsive Disorder

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Obsessive-Compulsive Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

All subjects will receive bilateral surgical implantation of DBS system

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

DBS

All subjects will undergo bilateral surgical implantation of DBS system to habenula. The DBS system will be active at one week after surgery.

Group Type EXPERIMENTAL

Bilateral surgical implantation of DBS system to habenula

Intervention Type DEVICE

The DBS device utilized in the present study may include the Medtronic, PINS and SceneRay DBS device depending on patients' choice.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Bilateral surgical implantation of DBS system to habenula

The DBS device utilized in the present study may include the Medtronic, PINS and SceneRay DBS device depending on patients' choice.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosed as having primary OCD according to DSM-IV criteria using the Structured Clinical Interview for DSM-IV Axis I disorders;
* YBOCSII score ≥31；
* Duration ≥2 years；
* Refractoriness to therapy was defined as no response or insufficient response following at least 2 treatments with adequate trials or intolerance to two or three selective serotonin transporter inhibitors (SSRIs) and clomipramine, augmentation strategies (antipsychotics) and cognitive behavioral therapy.
* Capacity to provide informed consent (understanding of the study purpose and methods.

Exclusion Criteria

* Except for those with major depressive disorder and mild anxiety disorders, patients with clinically significant comorbid DSM-IV diagnoses (such as schizophrenia, bipolar II disorder, alcohol or substance abuse in the last 6 months, current tic disorder, or body dysmorphic disorder)
* Patients with severe personality disorders, assessed using the Structured Clinical Interview for DSM-IV Axis II disorders.
* Serious and unstable organic diseases (e.g. unstable coronal heart disease);
* Pregnancy and/or lactation.

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No